Pentixapharm Holding AG N (PTP.DE)
- Previous Close
2.8700 - Open
2.9750 - Bid 2.9050 x --
- Ask 2.9800 x --
- Day's Range
2.8850 - 3.0500 - 52 Week Range
2.3750 - 5.1500 - Volume
9,988 - Avg. Volume
25,462 - Market Cap (intraday)
71.907M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.72
Pentixapharm Holding AG operates as a clinical-stage radiopharmaceutical development company. It focuses on developing CXCR4 ligand-based radiopharmaceutical approaches for diagnostic and therapeutic programs in various hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. The company's clinical pipeline includes PentixaTher, an Yttrium-90-based therapeutic against non-Hodgkin lymphomas; and PentixaFor, a Gallium-68-based companion diagnostic. Its clinical studies for compounds have commenced in Europe, including a dose-finding study for PentixaTher and a Phase III registration study for PentixaFor in marginal zone lymphoma. In addition, the company's PentixaFor is being developed as a diagnostic tool for primary aldosteronism, a cause of hypertension. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.
www.pentixapharm.comRecent News: PTP.DE
View MorePerformance Overview: PTP.DE
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTP.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTP.DE
View MoreValuation Measures
Market Cap
69.92M
Enterprise Value
57.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
690.90
Price/Book (mrq)
1.54
Enterprise Value/Revenue
558.00
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.4M
Net Income Avi to Common (ttm)
-13.97M
Diluted EPS (ttm)
-0.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
23.23M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--